AstraZeneca’s Ultomiris Showed Zero Relapses In Patients With Chronic Disorder Of Brain, Spinal Cord
AstraZeneca Plc (NASDAQ:AZN) posted detailed results from the Phase 3 CHAMPION-NMOSD trial of Ultomiris (ravulizumab) For neuromyelitis optica spectrum disorder (NMOSD). NMOSD…